Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. 2020. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html. Accessed 23 Mar 2022.
Imtiaz S, Nafeh F, Russell C, Ali F, Elton-Marshall T, Rehm J. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. Subst Abus Treat Prev Policy. 2021;16(1):87.
BC Coroners Service. Illicit drug toxicity deaths in BC. 2022.
United Nations Office on Drugs and Crime. COVID-19 and the drug supply chain: from production and trafficking to use. 2020.
Centre for Addiction and Mental Health. Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder. 2021.
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550–j1550.
Nosyk B, Marsh DC, Sun H, Schechter MT, Anis AH. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996–2006. J Subst Abuse Treat. 2010;39(1):22–31.
Klimas J, Hamilton MA, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10(1):216.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD002207.pub4.
Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(3):954–63.
Maina G, Tahir H, Docabo A, Kahia N, Brunelle C. Exploring health-care providers’ experiences in the care of clients on opioid agonist treatment in two western Canadian clinics. Can J Nurs Res. 2019;52(1):15–24.
Vurthy VH. Facing addiction in the United States: the surgeon general’s report of alcohol, drugs, and health. JAMA. 2017;317(2):133–4.
Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-63.
Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35.
Chatterjee A, Yu EJ, Tishberg L. Exploring opioid use disorder, its impact, and treatment among individuals experiencing homelessness as part of a family. Drug Alcohol Depend. 2018;188:161–8.
Andraka-Christou B, Bouskill K, Haffajee RL, Randall-Kosich O, Golan M, Totaram R, et al. Common themes in early state policy responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse. 2021;47(4):486–96.
British Columbia Centre on Substance Use, BC Ministry of Health, Ministry of Mental Health and Addictions. Risk mitigation in the context of dual health emergencies—interim clinical guidance: update. 2022.
Centre for Addiction and Mental Health. COVID-19 opioid agonist treatment guidance. 2021.
Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021;93: 103237.
Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study. J Subst Abuse Treat. 2021;129: 108374.
Wood E, Kerr T, Marshall B, Li K, Zhang R, Hogg R, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009. https://doi.org/10.1136/bmj.b1649.
Hayashi K, Milloy MJ, Lysyshyn M, DeBeck K, Nosova E, Wood E, et al. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 2018;183:1–6.
Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC, Montaner JSG, et al. Methodology for evaluating Insite: Canada’s first medically supervised safer injection facility for injection drug users. Harm Reduct J. 2004;1(1):9.
Broderick JE, DeWitt EM, Rothrock N, Crane PK, Forrest CB. Advances in patient-reported outcomes: the NIH PROMIS(®) measures. EGEMS. 2013;1(1):12.
Merskey H. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Pain. 1986;Suppl 3:226.
Nosyk B, MacNab YC, Sun H, Fischer B, Marsh DC, Schechter MT, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009;170(6):783–92.
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend. 2013;132(1):378–82.
Peles E, Schreiber S, Sason A, Adelson M. Similarities and changes between 15- and 24-year survival and retention rates of patients in a large medical-affiliated methadone maintenance treatment (MMT) center. Drug Alcohol Depend. 2018;185:112–9.
Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, Liu Y, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94:41–6.
Lake S, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, et al. Methadone dose, cannabis use, and treatment retention: findings from a community-based sample of people who use unregulated drugs. J Addict Med. 9900. https://journals.lww.com/journaladdictionmedicine/Fulltext/9900/Methadone_Dose,_Cannabis_Use,_and_Treatment.32.aspx.
Moallef S, Homayra F, Milloy MJ, Bird L, Nosyk B, Hayashi K. High prevalence of unmet healthcare need among people who use illicit drugs in a Canadian setting with publicly-funded interdisciplinary primary care clinics. Subst Abus. 2020. https://doi.org/10.1080/08897077.2020.1846667.
Voon P, Wang L, Nosova E, Hayashi K, Milloy MJ, Wood E, et al. Greater pain severity is associated with inability to access addiction treatment among a cohort of people who use drugs. J Pain Res. 2020;13:2443–9.
Hyshka E, Anderson JT, Wild TC. Perceived unmet need and barriers to care amongst street-involved people who use illicit drugs. Drug Alcohol Rev. 2017;36(3):295–304.
Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict. 2013;22(3):261–5.
Mirzoev T, Kane S. What is health systems responsiveness? Review of existing knowledge and proposed conceptual framework. BMJ Glob Health. 2017;2(4): e000486.
Valentine N, de Silva A, Kawabata K, Darby C, Murray C, Evans D. Health system responsiveness: concepts, domains and operationalization. Health system performance, debates, methods and empiricism. Geneva: World Health Organization; 2003.
留言 (0)